(Alliance News) - PureTech Health PLC on Wednesday said it has acquired LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases.
LYT-100 was acquired from an undisclosed pharmaceutical company. No financial details of the acquisition were disclosed.
The biopharmaceutical company said LYT-100 expands its internal research & development pipeline and continues its progress in developing new medicines for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.
"There are no approved drug therapies on the market that can treat lymphedema. PureTech is working to address this need by pioneering an approach designed to target the underlying fibrosis and inflammation affecting the lymphatics to potentially improve lymphatic function and decrease the symptoms of lymphedema," said Chief Scientific Officer Joe Bolen.
Lymphedema is one of the most common lymphatic diseases. It is a chronic condition that is characterised by severe swelling in parts of the body - usually in the arms or legs - due to the build-up of lymph fluid and inflammation, fibrosis, and adipose deposition.
LYT-100, an oral small molecule with well-established preclinical anti-fibrotic activity, has been previously studied in healthy volunteers as part of a first phase, single ascending dose study.
PureTech said it will continue clinical development in healthy volunteers, looking at additional safety and pharmacokinetics of LYT-100 prior to initiating a human biomarker and proof-of-concept study, which is expected in 2020.
The stock was trading 1.0% lower on Wednesday in London at 249.60 pence a share.
PureTech (PRTC)